Showing results (1821-1830 of 1,866) with videos related to
Sort By:
Pageof 187
Scientific Reports|November 2, 2017
miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndromeCarolin Wohlfarth, Stefanie Schmitteckert, Janina D Härtle, et al.Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 10, 2012
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelinesRobert W Carlson, D Craig Allred, Benjamin O Anderson, et al.Drug Safety|October 7, 2023
Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network StudyOskar Gauffin, Judith S Brand, Sara Hedfors Vidlin, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2016
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in OncologyWilliam J Gradishar, Benjamin O Anderson, Ron Balassanian, et al.JAMA Oncology|October 1, 2019
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJoseph A Sparano, Robert J Gray, Della F Makower, et al.Journal of the National Cancer Institute|September 28, 2020
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx TrialKathy S Albain, Robert J Gray, Della F Makower, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.Nature Immunology|February 16, 2023
Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell developmentStefanie Scherer, Susanne G Oberle, Kristiyan Kanev, et al.JCO Oncology Advances|May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 TrialMoriah Forster, Fengmin Zhao, Sarah Bell, et al.Pageof 187